Micronutrients in chronic heart failure

Current Heart Failure Reports

Volumn 10, Issue 1, 2013, Pages 46-53

  Krim, Selim R ^a,c   Campbell, Patrick ^a,c   Lavie, Carl J ^a,b,c   Ventura, Hector ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Coenzyme Q10; Heart failure; L carnitine; Micronutrients; Vitamins

Indexed keywords

25 HYDROXYVITAMIN D; ALDOSTERONE ANTAGONIST; ALPHA TOCOPHEROL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CARNITINE; COBALAMIN; COLECALCIFEROL; COPPER; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOCALCIFEROL; FOLIC ACID; PALMITOYLCARNITINE; PLACEBO; PYRIDOXINE; RETINOL; RIBOFLAVIN; SELENIUM; THIAMINE; TRACE ELEMENT; UBIDECARENONE; VITAMIN B COMPLEX; VITAMIN D; ZINC;

ARTICLE; CACHEXIA; CARDIOVASCULAR MORTALITY; CONGESTIVE CARDIOMYOPATHY; DIETARY INTAKE; DISEASE COURSE; EXERCISE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART OUTPUT; HEART STROKE VOLUME; HEART VOLUME; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); NEW YORK HEART ASSOCIATION CLASS; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; SYSTOLIC HEART FAILURE; THIAMINE DEFICIENCY; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84873751083     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0118-4     Document Type: Article

References (91)

1. Heart Disease and Stroke Statistics-2011 Update. A report from the American Heart Association. Circulation. 2011;123:e18-209.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults; A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009, 14;53 (15): e1-e90.
3. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344-50.
4. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl Med. 2002;347:1397-402.
5. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050-3.
6. McKeag NA, McKinley MC, Woodside JV, Harbinson MT, McKeown PP. The role of micronutrients in heart failure. J Acad Nutr Diet. 2012;112:870-86. Review.
7. Witham MD. Vitamin D in chronic heart failure. Curr Heart Fail Rep. 2011;8:123-30.
8. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197-207.
9. Zittermann A, Schleithoff SS, Tenderich G, et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105-12.
10. Pilz S, Marz W, Wellnitz B, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008;93:3927-35.
11. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106:963-8. This large population-based cohort study showed a significant increase in risk of new-onset heart failure among patients with low 25(OH) vitamin D.
12. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754-9.
13. Cardus A, Panizo S, Encinas M, et al. 1, 25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis. 2009;204:85-9.
14. Lavie CJ, Lee JH, Milani RV. Vitamin D and cardiovascular disease: will it live up to its hype? J Am Coll Cardiol. 2011;58:1547-56.
15. Witham MD, Crighton LJ, Gillespie ND, et al. The effects of vitamin D supplementation on physical function and quality of life in older heart failure patients: a randomised controlled trial. Circ Heart Fail. 2010;3:195-201. This was the first published randomized controlled trial of vitamin D in older heart failure patients. No significant improvement was seen on exercise capacity, quality of life, or TNF- alpha levels despite doubling of 25OHD levels. However, natriuretic peptides did decrease in the study group.
16. Ameri P, Ronco D, Casu M, et al. High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure. Nutr Metab Cardiovasc Dis. 2010;20:633-40.
17. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18-28.
18. Gotsman I, Shauer A, Zwas DR, et al. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail. 2012;14:357-66.
19. Gropper SAS, Smith JL, Groff JL. Advanced nutrition and human metabolism. 4th ed. Belmont: Thomson/Wadsworth; 2005.
20. Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. Am J Med. 1991;91:151-5.
21. Zenuk C, Healey J, Donnelly J, Vaillancourt R, et al. Thiamine deficiency in congestive heart failure patients receiving long term furosemide therapy. Can J Clin Pharmacol. 2003;10:184-8.
22. Kwok T, Falconer-Smith JF, Potter JF, Ives DR. Thiamine status of elderly patients with cardiac failure. Age Ageing. 1992;21:67-71.
23. Hanninen SA, Darling PB, Sole MJ, Barr A, Keith ME. The prevalence of thiamine deficiency in hospitalized patients with congestive heart failure. J Am Coll Cardiol. 2006;47:354-61.
24. O'Keefe ST. Thiamine deficiency in elderly people. Age Ageing. 2000;29:99-101.
25. Pepersack T, Grabusinski J, Robberecht J, et al. Clinical relevance of thiamine status amoungst hospitalized elderly patients. Gerontology. 1999;45:96-101.
26. Lourenco BH, Viera LP, Macedo A, Nakasato M, et al. Nutritional status and adequacy of energy and nutrient intakes among heart failure patients. Arq Bras Cardiol. 2009;9:541-8.
27. Lemoine A, LeDevehat C, Codaccioni JL, et al. Vit B1, B2, B6 and C statuts in hospital inpatients. Am J Clin Nutr. 1980;33:2595-600.
28. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Ntur Metab Care. 2000;3:417-24.
29. Shimon I, Almog S, Vered Z, Seligmann H, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med. 1995;98:485-90.
30. Schoenenberger AW, Schoenenberger-Berzins R, de Maur CA, et al. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blinded, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012;101:159-64. The authors evaluated the effect of thiamine supplementation in patients with chronic heart failure. The primary outcome of the double blind, randomized cross-over trial was change in LVEF after receiving 300mg of thiamine for 4 weeks. They found a significant improvement in LVEF, an absolute increase of 3.9 %, after 28 days of oral supplementation.
31. Keith ME, Walsh MA, Darling PB, et al. B-vitmain deficiency in hospitalized patients with heart failure. J Am Diet Assoc. 2009;109:1406-10.
32. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50:3-32.
33. Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med. 2003;41:1444-54.
34. Arcand J, Floras V, Ahmed M, et al. Nutritional inadequacies in patients with stable heart failure. J Am Diet Assoc. 2009;109:1909-13.
35. Gorelik O, Almonznino-Sarafian D, Feder I, Wachsman O, et al. Dietary intake of various nutrients in older patients with congestive heart failure. Cardiology. 2003;99:177-81.
36. Catapano G, Pedone C, Nunziata E, et al. Nutrient intake and serum cytokine pattern in elderly people with heart failure. Eur J Heart Fail. 2008;10:428-34.
37. Mangoni AA, Sherwood RA, Asonganyi B, Swfit SG, et al. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens. 2005;18(2, pt1):220-6.
38. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanism largely independent of homocysteine lowering. Circulation. 2002;105:22-6.
39. Zafarullah H, Shahbbaz AU, Alturkmani R, et al. Elevated serum cobalamin in patients with decompensated biventricular failure. Am J Med Sci. 2008;336:383-8.
40. Cui R, Iso H, Chigusa D, et al. Dietary folate and Vitamin B6 and B12 Intake in Relation to mortality from Cardiovascular Diseases, Japan Collaborative Cohort Study. Stroke. 2010;41:1285-9. The study followed more than 59,000 patients for 14 years and assessed the effect of dietary intake of folate and B Vitamins on the risk of cardiovascular disease. The authors found that both folate and B6 were associated with significantly lower risk of death from Heart Disease, Stroke and coronary heart disease in Japanese patients.
41. Singh U, Devaraj S, Jialal I. Coenzyme Q10 supplementation and heart failure. Nutr Rev. 2007;65(6 part 1):286-93.
42. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9:273-84.
43. Pepe S, Marasco SF, Haas SJ, et al. Coenzyme Q10 in cardiovascular disease. Mitochondrion. 2007;7(suppl):S154-67.
44. Folkers K, Littaru GP, Ho L, Runge TM, Havanonda S, Cooley D. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int J Vitamin Res. 1970;40:380-90.
45. Littaru GP, Ho L, Folkers K. Deficiency of coenzyme Q10 in human heart disease, Part 1. Int J Vitamin Res. 1972;42:291-305.
46. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Invest. 1993;71S:116-23.
47. Folkers K, Baker L, Richardson PC, Shizukuishi S, Takamura K, Drzewoski J, Lewandowski J, Ellis JM: Biomedical and clinical aspects of coenzyme Q, Vol. 2 In: Yamamura Y, Folkers K, Ito Y, editors. Amsterdam: Elsevier/North Holland; 1980 p. 449.
48. Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J. 2006;27:2675-81.
49. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9:273-84.
50. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636-40.
51. Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors. 2005;25:137-45.
52. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med. 1997;18(suppl):S159-68.
53. Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12:464-72.
54. Mortensen A. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of «Q-symbio» - a multinational trial. Biofactors. 2003;18(1-4):79-89.
55. Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis. 1997;40:265-86.
56. Schonekess BO, Allard MF, Lopaschuk GD. Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res. 1995;77:726-34.
57. Broderick TL, Quinney HA, Lopaschuk GD. Carnitine stimulation of glucose oxida- tion in the fatty acid perfused isolated working rat heart. J Biol Chem. 1992;267:3758-63.
58. Abdel-aleem S, Sayed-Ahmed M, Nada MA, Hendrickson SC, St LJ, Lowe JE. Stimulation of non-oxidative glucose utilization by L-carnitine in isolated myocytes. J Mol Cell Cardiol. 1995;27:2465-72.
59. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol. 2000;95:75-83.
60. Regitz V, Shug AL, Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol. 1990;65:755-60.
61. Masumura Y, Kobayashi A, Yamazaki N. Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. Jpn Circ J. 1990;54:1471-6.
62. Soukoulis V, Dihu JB, Sole M, et al. Micronutrient deficiencies: an unmet need in heart failure. J Am Coll Cardiol. 2009;54:1660-73.
63. Vescovo G, Ravara B, Gobbo V, Dalla LL. Inflammation and perturbation of the l-carnitine system in heart failure. Eur J Heart Fail. 2005;7:997-1002.
64. El-Aroussy W, Rizk A, Mayhoub G, Aleem SA, El-Tobgy S, Mokhtar MS. Plasma carnitine levels as a marker of impaired left ventricular functions. Mol Cell Biochem. 2000;213:37-41.
65. Serati AR, Motamedi MR, Emami S, et al. L- carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. Cardiology. 2010;116:178-82.
66. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J. 2000;139:S120-3.
67. Ueland T, Svardal A, Oie E, et al. Disturbed carnitine regulation in chronic heart failure -Increased plasma levels of palmitoyl- carnitine are associated with poor prognosis. Int J Cardiol. 2012. doi: 10.1016/j.ijcard.2012. 04.150. Relatively large study showing a wide spectrum of disturbances in carnitine precursors and derivates in plasma in patients with chronic HF. In particular, free L-carnitine levels and its derivate palmitoyl-carnitine were increased in HF patients and significantly correlated with NT- proBNP and NYHA functional class. Moreover, high levels of palmitoyl-carnitine were independently associated with adverse outcome in these patients.
68. Oster O. Trace element concentrations (Cu, Zn, Fe) in sera from patients with dilated cardiomyopathy. Clin Chim Acta. 1993;214:209-18.
69. Cenac A, Simonoff M, Djibo A. Nutritional status and plasma trace elements in peripartum cardiomyopathy. A comparative study in Niger. J Cardiovasc Risk. 1996;3:483-7.
70. de Lorgeril M, Salen P, Accominotti M, et al. Dietary and blood antioxidants in patients with chronic heart failure. Insights into the potential importance of selenium in heart failure. Eur J Heart Fail. 2001;3(6):661-9.
71. Topuzoglu G, Erbay AR, Karul AB, Yensel N. Concentrations of copper, zinc, and magnesium in sera from patients with idiopathic dilated cardiomyopathy. Biol Trace Elem Res. 2003;95:11-7.
72. Kosar F, Sahin I, Taskapan C, et al. Trace element status (Se, Zn, Cu) in heart failure. Anadolu Kardiyol Derg. 2006;6:216-20.
73. Oster O, Prellwitz W, Kasper W, Meinertz T. Congestive cardiomyopathy and the selenium content of serum. Clin Chim Acta. 1983;128:125-32.
74. Chou HT, Yang HL, Tsou SS, Ho RK, Pai PY, Hsu HB. Status of trace elements in patients with idiopathic dilated cardiomyopathy in central Taiwan. Zhonghua Yi Xue Za Zhi (Taipei). 1998;61:193-8.
75. Navarro-Alarcon M, Lopez-Garcia de la Serrana H, Perez-Valero V, Lopez-Martinez C. Serum and urine selenium concentrations in patients with cardiovascular diseases and relationship to other nutritional indexes. Ann Nutr Metab. 1999;43:30-6.
76. Arroyo M, Laguardia SP, Bhattacharya SK, et al. Micronutrients in African-Americans with decompensated and compensated heart failure. Transl Res. 2006;148:301-8.
77. Malek F, Dvorak J, Jiresova E, Spacek R. Difference of baseline serum copper levels between groups of patients with different one year mortality and morbidity and chronic heart failure. Cent Eur J Public Health. 2003;11:198-201.
78. Alehagen U, Johansson P, Björnstedt M, et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. 2012. doi: 10.1016/j.ijcard.2012.04.156.
79. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with Congestive heart failure. JACC. 1998;31:1352-6.
80. Demirbag R, Yilmaz R, Erel O, Gultekin U, Aci D, Elbasan Z. The relationship between potency of oxidative stress and severity of dilated cardiomyopathy. Can J Cardiol. 2005;21:851-5.
81. Piccirillo G, Nocoo M, Moise A, et al. Influence of vitamin C on baro-reflex sensitivity in chronic heart failure. Hypertension. 2003;41:1240-5.
82. Ellis GR, Anderson RA, Chirkov YV, et al. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure: Effects of short- and long-term vitamin C therapy. J Am Coll Cardiol. 2000;36:1474-82.
83. Mak S, Overgaard CB, Newton GE. Effect of vitamin C and L-NMMA on the inotropic response to dobutamine in patients with heart failure. Am J Physiol Heart Circ Physiol. 2005;289:H2424-8.
84. Shinke T, Shite J, Takaoka H, et al. Vitamin C restores the contractile response to dobutamine and improves myocardial efficiency in patients with heart failure after anterior myocardial infarction. Am Heart J. 2007;154:645.e1-8.
85. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998;97:363-8.
86. Witte KK, Nikitin NP, Parker AC, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J. 2005;26:2238-44.
87. Giordano FJ. Oxygen, oxidative stress, hypoxia and heart failure. J Clin Invest. 2005;115:500-8.
88. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-8.
89. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol. 1996;28:506-14.
90. Lonn E, Bosch J, Yusuf S, Sheridan P, et al. HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293:1338-47.
91. Marchioli R, Levantesi G, Macchia A, Marfisi RM. et al; GISSI-Prevenzione Investigators. Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI Prevenzione trial. J Cardiovasc Med (Hagerstown). 2006;7:347-50.